How did OMER's Q4 2024 expenses impact its net profit?

Omeros Corporation's (OMER) Q4 2024 financial results show that the company incurred $23.32 million in Research and Development (R&D) expenses and reported a net loss of $31.36 million for the period.

The significant R&D expenses reflect Omeros' ongoing investment in developing new pharmaceutical products, which is a critical component of its business model. However, the negative net income indicates that the company has not yet achieved profitability in the quarter, as the expenses outweighed the revenue.

OMER R&D Expenses, Net Income